Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 12, 2022 08:15 ET | Source: BioCardia, Inc.

BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia

SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for...
June 15, 2022 08:00 ET | Source: BioCardia, Inc.

BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
May 11, 2022 16:15 ET | Source: BioCardia, Inc.

BioCardia Reports First Quarter 2022 Business Highlights and Financial Results

SUNNYVALE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
May 04, 2022 08:30 ET | Source: BioCardia, Inc.

BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022

SUNNYVALE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
April 12, 2022 07:15 ET | Source: BioCardia, Inc.

BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

SUNNYVALE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 29, 2022 16:05 ET | Source: BioCardia, Inc.

BioCardia Reports 2021 Financial Results and Recent Business Highlights

SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 24, 2022 08:00 ET | Source: BioCardia, Inc.

BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022

SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 22, 2022 08:30 ET | Source: BioCardia, Inc.

BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure

SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 01, 2022 08:00 ET | Source: BioCardia, Inc.

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
February 14, 2022 07:30 ET | Source: BioCardia, Inc.

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right